Efficacy of hepatitis A vaccination in immunocompromised travelers.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26720

Enrollment

600

Registered

2008-11-04

Start date

2009-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatits A vaccination immunosuppression Hepatitis A vaccinatie immuunsuppressie

Interventions

Boostervaccination of hepatitis A 2 weeks after first vacciantion.

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consecutive patients > 18 years of age using immunosuppressive medication who come to the travel clinics and need vaccination with hepatitis A according to LCR guidelines. - Immunosuppressive medication is defined as use of cyclosporine A, azathioprine, cyclophosphamide, methotrexate, TNF-á blockers, prednisone use eqal to 10 mg/day or a cumulative dose of > 700 mg., tacrolimus, mycophenolate mofetil. The study group will be compared with travelers > 18 years old that are immunocompetent.

Exclusion criteria

Exclusion criteria: 1. Allergy to the advised vaccine or its components.

Design outcomes

Primary

Measure	Time frame
- Antibody titres after booster vaccination.	—

Secondary

Measure	Time frame
- Antibody titres after first hepatitis A vaccination - Antibody production after the booster vaccination for hepatitis A - Determination of disease or medication related and demographic parameters that are predictive for decreased antibody production to hepatitis A vaccination.	—

Contacts

Public ContactA. Verbon

Maastricht University Medical Centre Department of Medical Microbiology PO Box 5800

a.verbon@mumc.nl+31 (0)43 3876644

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)